TY - CHAP M1 - Book, Section TI - Epidemiology, Pathophysiology, and Treatment of Hypertension A1 - Hall, Michael E. A1 - Hall, John E. A1 - Whelton, Paul K. A2 - Fuster, Valentin A2 - Narula, Jagat A2 - Vaishnava, Prashant A2 - Leon, Martin B. A2 - Callans, David J. A2 - Rumsfeld, John S. A2 - Poppas, Athena PY - 2022 T2 - Fuster and Hurst's The Heart, 15e AB - Content UpdateSustained Blood Pressure Reduction With the RNA Interference Therapeutic Zilebesiran: Primary Results From KARDIA-1, a Phase 2 Study in Patients With HypertensionThe KARDIA-1 trial was a randomized, blinded, phase 2 study of zilebesiran, an investigational long-acting RNA interference agent that inhibits hepatic angiotensinogen synthesis by reducing liver angiotensinogen mRNA levels. Read More SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesscardiology.mhmedical.com/content.aspx?aid=1205976292 ER -